Form SCHEDULE 13G/A ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
April 21, 2026 1:33 PM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,327.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "The broadening of Medicare coverage for the GLP-1 medications for obesity is a key driver of US market growth for LLYs Zepbound as weve previously discussed (see HERE and HERE). Recent commentary from UNH and CVS (see below; both stocks covered by Erin Wright) have raised some questions about the path to broader coverage via the CMS BALANCE program in 2027 following a 2026 bridge program (which begins July 1), which has... More
